Valuation: Evolutionary Genomics, Inc.

Market Cap 2.99M 2.67M 2.47M 2.24M 4.19M 284M 4.26M 29.73M 11.77M 149M 11.24M 11M 470M P/E 2021
-1.34x
P/E 2022 -2x
Enterprise Value 6.16M 5.5M 5.08M 4.61M 8.62M 585M 8.76M 61.17M 24.22M 306M 23.12M 22.63M 966M EV / Sales 2021
-
EV / Sales 2022 -
Free-Float
67.35%
Yield 2021 *
-
Yield 2022 -
1 day-27.14%
1 week+254,900.00%
Current month+254,900.00%
1 month+254,900.00%
3 months+254,900.00%
6 months+254,900.00%
Current year+254,900.00%
1 year 0
Extreme 0.0002
0.51
3 years 0
Extreme 0.0002
0.51
5 years 0
Extreme 0.0002
0.9
10 years 0
Extreme 0.0002
5.71
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 71 31/12/1999
Chief Executive Officer 70 30/09/2014
Director TitleAgeSince
Chairman 70 30/09/2014
Director/Board Member 76 31/12/1999
Director/Board Member 66 31/12/2009
Date Insider Type Main position Quantity % Market Cap. Importance
23/05/22 Exercice

Chief Executive Officer

185,715 2.8074%
23/05/22 Exercice

Founder

278,571 4.2111%
23/05/22 Exercice

Founder

55,714 0.8422%
Change 5-day change 1-year change 3-year change Capi.($)
-27.14%+254,900.00%+254,900.00%+13.33% 1.33K
+2.41%+0.29%+42.02%+71.57% 64.69B
-0.15%+7.50%+11.01%+73.48% 54.78B
+0.57%+4.60%+10.07%+92.86% 53.49B
+0.37%+4.67%+27.03%+52.07% 45.98B
-1.21%+2.32%+21.80%+123.81% 42.94B
-0.37%+5.07%+249.91%+918.74% 40.08B
+0.05%+0.21%+18.26%+58.53% 33.52B
-0.38%+5.68%+36.43%+27.54% 23.67B
+1.19%-4.98%+29.01%-0.65% 23.97B
Average -2.47%+2.17%+25,534.56%+143.13% 38.31B
Weighted average by Cap. +0.39%+2.73%+47.57%+158.58%

Financials

2021 2022
Net sales - -
Net income -2.79M -2.49M -2.3M -2.09M -3.91M -265M -3.97M -27.74M -10.98M -139M -10.49M -10.26M -438M -1.93M -1.73M -1.6M -1.45M -2.71M -184M -2.75M -19.21M -7.61M -96.24M -7.26M -7.11M -303M
Net Debt 3.53M 3.15M 2.91M 2.64M 4.94M 335M 5.02M 35.04M 13.87M 176M 13.25M 12.97M 553M 3.17M 2.83M 2.61M 2.37M 4.43M 301M 4.5M 31.44M 12.45M 158M 11.88M 11.63M 497M
Logo Evolutionary Genomics, Inc.
Evolutionary Genomics, Inc. is a genomics research and development company. The Company is focused on the identification and validation of genes that impact commercially valuable traits in crops for the agriculture industry. It has performed research on crops including rice, corn, soybeans, wheat, cotton, cowpeas, beans, tomatoes, and cassava. Its core technology is its patented Adapted Traits Platform (ATP), which is used to perform molecular evolution analysis to identify positively selected genes that may have an impact on traits of interest. Positively selected candidate genes must be further tested to validate their impact on the desired traits. The Company has applied its ATP in research projects, including identifying genes responsible for increases in yield in corn, increases in yield in rice, drought tolerance and sugar content in tomatoes and pest/disease resistance in soybeans, cassava, beans, tomatoes and cotton.
Employees
3
  1. Stock Market
  2. Stocks
  3. FNAM Stock